Quark Pharmaceuticals Announces First Patient Dosing By Pfizer In Phase II Trial Of RNAi Therapy In Diabetic Macular Edema

�Quark Pharmaceuticals, Inc., a
development-stage pharmaceutical company discovering and developing novel
RNA interference (RNAi)-based therapeutics, today announced that its
partner, Pfizer Inc, initiated patient dosing in a Phase II